The aim of this paper was to evaluate the impact of PAP as the second tier of CF NBS protocol, before the CFTR genetic analysis, on NBS outcomes and on detection of CRMS/CFSPID in an Italian region with a high prevalence of CRMS/CFSPID. This evidence concerns the gene CFTR and cystic fibrosis.